The utility of therapeutic plasma exchange in Hyperviscosity syndrome associated with juvenile rheumatoid arthritis: A case report

Author(s):  
Allen P. Green ◽  
Adam C. Gonzalez ◽  
Jack B. Alperin ◽  
James D. Burner ◽  
Sean G. Yates
2014 ◽  
Vol 50 (4) ◽  
pp. 407-410 ◽  
Author(s):  
Ahmet H. Gedik ◽  
Demet Demirkol ◽  
Burak Tatlı ◽  
Suleyman Bayraktar ◽  
Alpay Alkan ◽  
...  

2018 ◽  
Vol 57 (2) ◽  
pp. 225-227 ◽  
Author(s):  
Parvez M. Lokhandwala ◽  
Maryam Shabihkhani ◽  
Paul M. Ness ◽  
Evan M. Bloch

2002 ◽  
Vol 7 (5) ◽  
pp. 570-573 ◽  
Author(s):  
Satoshi Imaizumi ◽  
Tetsuro Morita ◽  
Hiroto Kobayashi ◽  
Takui Ito ◽  
Yasuharu Hirata

1997 ◽  
Vol 46 (4) ◽  
pp. 978-982
Author(s):  
Kei Koga ◽  
Takashi Ishinishi ◽  
Kousuke Ogata ◽  
Michiya Hara ◽  
Kazuhiko Saeki

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Hannelore Sprenger-Mähr ◽  
Emanuel Zitt ◽  
Afschin Soleiman ◽  
Karl Lhotta

Recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation is difficult to treat. Recently a series of four patients unresponsive to plasma exchange (PE) and rituximab, who were successfully treated with abatacept, has been reported. We present a 26-year-old Caucasian patient who suffered from juvenile rheumatoid arthritis and developed severe proteinuria eleven days after transplantation. An allograft biopsy was suggestive of recurrent focal segmental glomerulosclerosis. He did not respond to PE therapy. A first dose of abatacept produced partial remission. Four weeks later proteinuria again increased and a second biopsy showed progression of disease. After another ineffective course of PE he was given a second dose of abatacept, which was followed by rapid, complete, and sustained resolution of proteinuria. This treatment caused a significant increase in BK and JC viremia. Whether abatacept ameliorated proteinuria via an effect on podocytes or on the patient’s primary disease remains speculative.


Sign in / Sign up

Export Citation Format

Share Document